194 / 220
2. Garbe C, B
€
uttner P, Bertz J, et al. Primary cutaneous melanoma. Identifica-
tion of prognostic groups and estimation of individual prognosis for 5093
patients.
Cancer
1995;75:2484–2491.
3. Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features
and prognostic factors of cutaneous head and neck melanoma: a
population-based study.
Arch Otolaryngol Head Neck Surg
2007;133:442–
447.
4. Shashanka R, Smitha BR. Head and neck melanoma.
ISRN Surg
2012;
2012:948302.
5. Kienstra MA, Padhya TA. Head and neck melanoma.
Cancer Control
2005;12:242–247.
6. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An
analysis of 405 cases.
Am J Surg
1970;120:425–431.
7. Evans MS, Drabick JJ. Systemic treatment in the management of head and
neck cutaneous malignancies.
Oper Tech Otolaryngol Head Neck Surg
2013;24:63–68.
8. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant ther-
apy in patients with high-risk melanoma: a systematic review and meta-
analysis.
J Natl Cancer Inst
2010;102:493–501.
9. Patel JN, Walko CM. Sylatron: a pegylated interferon for use in melanoma.
Ann Pharmacother
2012;46:830–838.
10. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way
is a key to eliciting potent antitumor immunity.
Front Oncol
2014;4:74.
11. Forbes NE, Krishnan R, Diallo JS. Pharmacological modulation of anti-
tumor immunity induced by oncolytic viruses.
Front Oncol
2014;4:191.
12. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a
second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor.
Clin Cancer Res
2006;12:6737–6747.
13. Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of
granulocyte-macrophage colony-stimulating factor in the immunotherapy
of melanoma.
J Immunother Cancer
2014;2:11.
14. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a
granulocyte-macrophage colony-stimulating factor-encoding, second-gen-
eration oncolytic herpesvirus in patients with unresectable metastatic mela-
noma.
J Clin Oncol
2009;27:5763–5771.
15. Ross MI, Andtbacka RHI, Puzanov I, et al. Patterns of durable response
with intralesional talimogene laherparepvec (T-VEC): results from a phase
III trial in patients with stage IIIb-IV melanoma.
J Clin Oncol
2014;
32(suppl):abstract 9026.
16. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec
improves durable response rate in patients with advanced melanoma.
J Clin
Oncol
2015;33:2780–2788.
17. Andtbacka RH, Ross MI, Delman K, et al. Responses of injected and unin-
jected lesions to intralesional talimogene laherparepvec (T-VEC) in the
OPTiM study and the contribution of surgery to response. Ann Surg Oncol
2014;21(suppl 1):abstract 52.
18. Andtbacka RHI, Collichio FA, Amatruda T, et al. Final planned overall sur-
vival (OS) from OPTiM, a randomized phase III trial of talimogene laher-
parepvec (T-VEC) versus GM-CSF for the treatment of unresected stage
IIIB/C/IV melanoma (NCT00769704).
J Immunother Cancer
2014;2(Suppl
3):P263.
19. World Health Organization. WHO handbook for reporting results of cancer
treatment. Geneva, Switzerland: World Health Organization; 1979.
20. Hayes AJ, Clark MA, Harries M, Thomas JM. Management of in-transit
metastases from cutaneous malignant melanoma.
Br J Surg
2004;91:
673–682.
21. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemur-
afenib in melanoma with BRAF V600E mutation.
N Engl J Med
2011;364:
2507–2516.
22. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated
metastatic melanoma: a multicentre, open-label, phase 3 randomised con-
trolled trial.
Lancet
2012;380:358–365.
23. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibi-
tor trametinib in patients with advanced melanoma: a phase 1 dose-
escalation trial.
Lancet Oncol
2012;13:782–789.
24. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobime-
tinib in BRAF-mutated melanoma.
N Engl J Med
2014;371:1867–1876.
25. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimu-
mab in patients with metastatic melanoma.
N Engl J Med
2010;363:
711–723.
26. Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1
monoclonal antibody MK-3475 in 411 patients (pts) with melanoma
(MEL).
J Clin Oncol
2014;32:abstract LBA9000.
27. Weber JS, Minor DR, D’Angelo SP, et al. A phase 3 randomized, open-
label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus
investigator’s choice chemotherapy (ICC) in patients with advanced mela-
noma after prior anti-CTLA-4 therapy.
Ann Oncol
2014;25(suppl 4):
LBA3_PR.
O
NCOLYTIC IMMUNOTHERAPY IN CUTANEOUS HEAD AND NECK MELANOMA
HEAD & NECK—DOI
10.1002/hed
174